2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Competitive Advantage

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the historic period include the aging population, high incidence of diabetes, increased awareness and early diagnosis, global eye health initiatives, innovations in pharmaceuticals, and patient advocacy and support.

How Big Is the Macular Edema and Macular Degeneration Market Size Expected to Grow by 2029?
In the coming years, the macular edema and macular degeneration market is anticipated to witness significant growth, expanding to $13.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. This growth in the projected period can be credited to personalized medicinal tactics, increasing consciousness in up-and-coming markets, emphasis on combination treatments, and collaboration with teleophthalmology services and rapidly aging global population. The progress trend for the estimated period encompasses advancements in extended-release medicine delivery, integration of gene therapies, innovation in imaging technologies, individualized treatment strategies based on biomarkers, use of teleophthalmology for distant monitoring, and enhancements in artificial intelligence techniques for diagnostic purposes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

Which Key Market Drivers Powering Macular Edema and Macular Degeneration Market Expansion and Growth?
The growth of the macular edema and macular degeneration market is anticipated to be championed by the swelling demographic afflicted by diabetes. This chronic ailment is marked by elevated glucose levels in the blood, which inflicts damage to the ocular blood vessels, precipitating macular edema and macular degeneration. The National Health Service (NHS England), a UK-based state-funded healthcare organization, discerned in June 2024 that pre-diabetes individuals positively diagnosed by the NHS in England had shot up by 18% in 2023 to 3,615,330 from 3,065,825 in the previous year. In the age bracket of those under 40, the rates vaulted up by nearly 25%, escalating from 173,166 to 216,440. Consequently, the growing cadre of people with diabetes is fueling the expansion of the macular edema and macular degeneration market. The expansion of the macular edema and macular degeneration market is projected to be spurred on by the rising prevalence of eye disorders. Encompassing a host of conditions that compromise the visual system, these disorders herald visual impairment and other manifestations. These eye disorders can trigger macular edema by instigating fluid leakage in the macula. The abnormal vasculature growth typical of wet AMD results in macular fluid build-up. In September 2023, a report released by National Eye Health Week (a UK government site) reported that late-stage age-related macular degeneration, the primary cause of blindness in the UK, is slated to surge by 25% by 2032, while early-stage AMD (drusen) will rise by 16%, cataracts by 25%, and glaucoma by 17% by 2032. Hence, the heightened prevalence of eye disorders is driving the expansion of the macular edema and macular degeneration market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Macular Edema and Macular Degeneration Market?
Key players in the macular edema and macular degeneration industry are working on the creation of unique products like Vabysmo (faricimab-svoa), with a goal of enhancing their market profitability. Vabysmo (faricimab-svoa), a treatment drug for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), received approval from the Food and Drug Administration in January 2022. This approval was given to Genentech Inc., an American biotech company. The drug is a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), making it the inaugural bispecific monoclonal antibody addressing both conditions. The drug faricimab has the potential to be a game-changer in the treatment of nAMD and DME. Its approval by the FDA and EU signifies an important achievement for Genentech and Roche.

What Are the Emerging Segments in the Macular Edema and Macular Degeneration Market?
The macular edema and macular degeneration market covered in this report is segmented -

1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration
3) By End User: Hospitals, Clinics, Other End Users

Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

Who Are the Global Leaders in the Macular Edema and Macular Degeneration Market?
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

Which are the Top Profitable Regional Markets for the Macular Edema and Macular Degeneration Industry?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.